论文部分内容阅读
阿司匹林是缺血性脑卒中预防及治疗中应用最为广泛的抑制血小板聚集药物。但接受规范阿司匹林应用的患者并不都能达到预期效果，此现象称为阿司匹林抵抗（ AR）。阿司匹林抑制血小板聚集是一个错综复杂的过程，产生 AR 的机制亦复杂，可能涉及血小板聚集过程的多个环节。基因多态性影响蛋白的结构或构象，从而影响阿司匹林对不同个体的抗血小板聚集作用。 AR与基因多态性的关系是目前研究的热点，该文主要介绍与缺血性脑卒中发生 AR 相关的基因多态性。期望未来临床中进行AR相关基因多态性分析，使得临床医师有可能按照基因多态性的特点，以制订个体化最佳的药物治疗方案，减少缺血性脑卒中的发生和发展，也可对可能发生缺血性脑卒中患者进行预测以降低脑血管病的发生风险。“,”Aspirin is the most widely used inhibitor of platelet aggregation in the prevention and treat-ment of ischemic stroke.However,there are patients who did not achieve the expected effect from the stand-ard aspirin treatment,which is called aspirin resistance(AR).Aspirin inhibiting platelet aggregation is a complex process,and the mechanism of AR is complex and may involve many aspects of platelet aggregation . Gene polymorphism affects the structure or conformation of the protein ,which affects the effect of aspirin on platelet aggregation in different individuals .The relationship between AR and genetic polymorphism is a hot research topic,and here mainly introduces the gene polymorphism of AR associated with ischemic stroke .It is expected that the research on polymorphism of AR gene will make it possible for clinicians in the future to develop optimal drug treatment program to reduce the occurrence and development of ischemic stroke , and reduce risks for cerebrovascular diseases from prediction .